Literature DB >> 2472869

Distribution of acid stable trypsin inhibitor immunoreactivity in normal and malignant human tissues.

E Yoshida1, H Sumi, M Maruyama, H Tsushima, Y Matsuoka, M Sugiki, H Mihara.   

Abstract

The distribution and localization of acid stable trypsin inhibitor (ASTI) in normal and malignant human tissues from various organs were examined using immunohistochemical techniques that used goat antibody raised against highly purified ASTI from human urine. Tissues were assessed as positive only when they were stained by both the biotin-avidin-peroxidase complex system and biotin-streptavidin-beta-galactosidase complex system, and the staining was abolished by absorption with purified ASTI. Under normal conditions, ASTI immunoreactivity was observed in only a few organs. Positive tissues for ASTI immunoreactivity included the kidney proximal tubules, glial cells of the cerebrum, fibrillar structures of the lamina propria of the stomach and colon, and bronchial epithelial cells. No ASTI immunoreactivity was observed in the cardiovascular system, reproductive system, or other tissues examined. As is not the case for normal tissues, ASTI immunoreactivity was found to be widely distributed in malignant tumors. Staining was observed in the extracellular space, i.e., in the stroma of the tumor and in connective tissues around the tumor invasion, whereas no ASTI immunoreactivity was detected in the malignant cells. Considering the identity of the first 36 NH2-terminal residues of ASTI purified from plasma or urine with a recently reported endothelial cell growth factor, the present findings suggest that ASTI could play an important role, not limited to its function as a protease inhibitor, in the invasive growth of malignant neoplasms.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2472869     DOI: 10.1002/1097-0142(19890815)64:4<860::aid-cncr2820640417>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Anti-inflammatory and chondroprotective effect of TSG-6 (tumor necrosis factor-alpha-stimulated gene-6) in murine models of experimental arthritis.

Authors:  T Bárdos; R V Kamath; K Mikecz; T T Glant
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

2.  Intra-alveolar urinary trypsin inhibitor cannot inhibit polymorphonuclear elastase activity in the lung in postsurgical patients with acute respiratory distress syndrome.

Authors:  M Nakane; H Iwama
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

3.  Distribution and localization of inter-alpha-trypsin inhibitor and its active component acid-stable proteinase inhibitor: comparative immunohistochemical study.

Authors:  E Yoshida; H Sumi; H Tsushima; M Maruyama; H Mihara
Journal:  Inflammation       Date:  1991-02       Impact factor: 4.092

4.  Acid-stable protease inhibitor in chronic phase of carrageenin-induced inflammation in rats.

Authors:  M Sugiki; M Maruyama; E Yoshida; H Sumi; H Mihara
Journal:  Inflammation       Date:  1991-08       Impact factor: 4.092

5.  Ontogeny of inter-alpha inhibitor proteins in ovine brain and somatic tissues.

Authors:  Mariya S Spasova; Grazyna B Sadowska; Steven W Threlkeld; Yow-Pin Lim; Barbara S Stonestreet
Journal:  Exp Biol Med (Maywood)       Date:  2014-06

6.  Immunohistochemical demonstration of bikunin, a light chain of inter-alpha-trypsin inhibitor, in human brain tumors.

Authors:  E Yoshida; M Maruyama; M Sugiki; H Mihara
Journal:  Inflammation       Date:  1994-12       Impact factor: 4.092

7.  Ontogeny of inter-alpha inhibitor protein (IAIP) expression in human brain.

Authors:  Boram Kim; Suzanne De La Monte; Virginia Hovanesian; Aparna Patra; Xiaodi Chen; Ray H Chen; Miles C Miller; Mehmet Halit Pinar; Yow-Pin Lim; Edward G Stopa; Barbara S Stonestreet
Journal:  J Neurosci Res       Date:  2019-12-04       Impact factor: 4.164

8.  Characterization of uronic-acid-rich inhibitor of calcium oxalate crystallization isolated from rat urine.

Authors:  F Atmani; S R Khan
Journal:  Urol Res       Date:  1995
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.